OncoLink at ASCO 2001: Saturday, May 12

Managing Editor, Maggie Hampshire, RN, BSN, OCN helps conference goers fill-out the OncoLink/Elsevier Survey.

A Prospective Randomized Trial of Prophylactic Platelet Transfusion and Bleeding Incidence in Hematopoietic Stem Cell Transplant (HSCT) Recipients: 10, 000 μL vs. 20,000 μL Threshold Presenter: M.S. Zumberg Affiliation: University of Florida College of Medicine Background: Threshold of Prophylactic Platelet Transfusion (PPT) for HSCT has yet to be determined One retrospective review in bone marrow transplant patients showed...
A Randomized, Double-blind, Phase III Study Evaluating Fixed Dose, Once-Per-Cycle Pegylated Filgrastim (SD/01) vs Daily Filgrastim to Support Chemotherapy for Breast Cancer Presenter: M. Green Affiliation: Multicenter Trial Background: It has been shown prolonged neutropenia associated with chemotherapy administration can be significantly decreased by daily Filgrastim. Pegylated Filgrastim is a sustained...
A single Dose of Pegylated Filgrastim (SD/01) is as effective as Daily Filgrastim for Hematologic Support of Chemotherapy in Breast Cancer Patients: Results of a Randomized,k Double-Blind, Phase 3 Trial Presenter: F.A. Holmes Affiliation: US Oncology, Houston, TX Background: Neutropenia is a frequent result of cytotoxic chemotherapy and increases patient risk for serious infection and treatment failure due to dose-reduction or delay....
Amifostine (AF) Cytoprotetion (CP) of Escalating Doses of Melphalan (MEL) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Final Results of a Phase I & II study Presenter: G. L. Phillips Affiliation: University of Maryland / Greenebaum Cancer Center Background: Alkylating agents show a steep dose response curve. Regimen related toxicity (RRT) is dose- limiting with AHSCT Growth factors and stem cell ...
An EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC) Presenter: J. P. Van Meerbeeck Affiliation: EORTC Background: Combination chemotherapy improves survival in advanced NSCLC based on numerous reports. Cisplatin based chemotherapy has remained the standard regimen used in most studies. This ...
ASCO/European Society for Medical Oncology Joint Session Addresses the Clinical and Ethical Implications of the Human Genome Project A panel of American and European presenters came together Saturday afternoon in a special joint session to share perspectives on how the sequencing of the Human Genome will likely affect the clinical practice of oncology is practiced in the...
Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung...
Efficacy of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Reducing Mucositis in Patients with Hematologic Malignancies Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation (auto-PBPCT) After Radiation-Based Conditioning ? Resu Presenter: R. T. Spielberger Affiliation: City of Hope National Medical Center, Duarte, CA Background: TBI/VP16/Cyclophosphamide is the established conditioning regimen for auto-PBPCT and it causes approximaetly 80% of severe oral mucositis....
Health outcomes following primary Androgen therapy in a population-based cohort Presenter: K. B. Knopf Affiliation: National Cancer Institute, Bethesda, MD Background: There are scant data on how quality of life is affected among men with prostate cancer who have no symptoms related to the tumor but are receiving adjuvant...
How Much Chemotherapy Are Cancer Patients Receiving at the End of Life? Presenter: E.J. Emanuel Affiliation: National Institutes of Health Background: End of life issues are an important part of oncology care. This study was performed to determine the proportion of cancer patients getting chemotherapy at the...
Informed consent to cancer clinical trials Presenter: S. Joffe Affiliation: Dana-Farber Cancer Institute, Boston, MA Background: For valid informed consent to be obtained, the prospective subject must have an understanding of the medical and research issues involved to make an informed...
Keeping cancer guidelines current: results of a comprehensive prospective literature monitoring strategy Presenter: M.C. Brouwers/G. P.Browman Affiliation: McMaster University, Hamilton Regional Cancer Centre, Hamilton, Canada Background: A Clinical Practice Guideline (CPG) is an evidence-based statement that assists patients and health care...
Myelodysplastic (MDS) Syndrome and Leukemia After Autotransplantation for Lymphoma: a Multicenter Case-Control Study Presenter: D. J. Rizzo Affiliation: NCI, Bethesda, MD Background: Increased survival has been seen in pateints with Hodgkin?s disease and Non-Hodgkin?s lymphoma who underwent autotransplantation, with a 40-50% long-term disease-free-survival...
Non-Adherence with Adjuvant Tamoxifen Therapy in Women with Early Stage Breast Cancer Presenter: A. H. Partridge, P. S. Wang, E. P. Winer, J. L. Avorn Affiliation: Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA Background: Tamoxifen has been shown to help prevent breast cancer recurrence and...
Opening Address: NCI Director Dr. Richard Klausner Welcomes ASCO Members Saturday morning, National Cancer Institute Director Richard Klausner, MD, welcomed attendees to the ASCO annual meeting by also welcoming them into what he sees as a new era for oncology: the so-called "post-genomic era." With the completion...
Providing Audiotapes of Primary Adjuvant Treatment Consultations to Women with Breast Cancer: a Multi-Site Randomized Controlled Trial Presenter: T. Hack Affiliation: University of Manitoba, Winnipeg, MB, Canada; British Columbia Cancer Agency, Vancouver; BC, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada; Cross Cancer Institute, Edmonton, AB, Canada Background: Patient...
Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung...
Satisfaction and anxiety are improved with the use of an easy-to-read informed consent document: a randomized multi-group study Presenter: P. C. Raich Affiliation: AMC Cancer Research Center, Denver, CO Background: Informed consent is a process in which the patient is given all the information needed to decide whether to participate in a clincal trial. The signing of the...
The Effect of Hospital Volume and Socioeconomic Status on Colostomy Rates for Rectal Cancer Presenter: D. C. Hodgson Affiliation: Background: Loss of sphincter function due to rectal cancer is associated with significant impairment in the quality of a patient?s life. This study evaluated the impact of surgical case-volume or patient...
The Quality of Non-Cancer Care Delivered to Elderly Breast Cancer Survivors Presenter: C.C. Earle, H. f Burstein, F. P. Winer, J. C. Weeks Affiliation: Dana-Farber Cancer institute, Boston, MA Background: There are currently more than 2 million breast cancer survivors in the US; as screening and treatment improve we...